XNK Therapeutics
Huddinge
About XNK Therapeutics
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company's platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow's cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $21.8M
- Last round: Grant (Oct 2023)
- Website: xnktherapeutics.comen
- Phone: [email protected]
Industries & Categories
Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/xnk-therapeutics-131689 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.